Review Article

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

Table 1

Design of the six main randomized trials of etravirine.

Trial [ref]Treatment arms InclusionDurationPrimary endpoint

DUET [26, 27]BR + ETR Experienced96 weeksHIV RNA <50 c/mL
BR + placebo

SENSE [28]2NRTI + ETR Naïve48 weeksCNS adverse events
2NRTI + EFV

UK SSAT029 [29]2NRTI + ETR HIV RNA <5024 weeksCNS adverse events
2NRTI + EFV

Swiss SWITCH-EE [30]2NRTI + ETR HIV RNA <5012 weeksPatient satisfaction
2NRTI + EFV

ETRA-SWITCH [31]2NRTI + ETR HIV RNA <5048 weeksHIV RNA <50 c/mL
2NRTI + PI/r